Global Gene Therapy On Cardiovascular Disease Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch＇s in-depth investigation and research, the global Gene Therapy On Cardiovascular Disease market size will reach 599.86 Million USD in 2025 and is projected to reach 25,405.69 Million USD by 2032, with a CAGR of 70.77% (2025-2032). Notably, the China Gene Therapy On Cardiovascular Disease market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Gene therapy for cardiovascular diseases involves the use of genetic interventions to address underlying issues contributing to heart-related disorders. This therapeutic approach aims to modify or introduce specific genes to improve the function of the cardiovascular system. In the context of cardiovascular diseases, gene therapy may target conditions such as ischemic heart disease, heart failure, or genetic disorders affecting cardiac function. Strategies include enhancing blood vessel formation, promoting cell survival, or modulating the expression of genes associated with cardiac health. Researchers are exploring gene therapy approaches to improve angiogenesis, reduce inflammation, and enhance myocardial function. While gene therapy for cardiovascular diseases is still in the experimental stage, early clinical trials and preclinical studies suggest the potential for novel treatment options to address the complex mechanisms involved in these conditions, offering hope for more effective and targeted interventions in the future.
The major global suppliers of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics, bluebird bio, Sunway Biotech, SIBIONO, AnGes, Human Stem Cells Institute, Orchard Therapeutics, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Gene Therapy On Cardiovascular Disease. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Gene Therapy On Cardiovascular Disease market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Gene Therapy On Cardiovascular Disease market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Gene Therapy On Cardiovascular Disease industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Gene Therapy On Cardiovascular Disease Include:
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Human Stem Cells Institute
Orchard Therapeutics
Gene Therapy On Cardiovascular Disease Product Segment Include:
Viral Gene Therapy
Non-Viral Gene Therapy
Gene Therapy On Cardiovascular Disease Product Application Include:
Neurological Diseases
Cancer
Other
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Gene Therapy On Cardiovascular Disease Industry PESTEL Analysis
Chapter 3: Global Gene Therapy On Cardiovascular Disease Industry Porter's Five Forces Analysis
Chapter 4: Global Gene Therapy On Cardiovascular Disease Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Gene Therapy On Cardiovascular Disease Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Gene Therapy On Cardiovascular Disease Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Gene Therapy On Cardiovascular Disease Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch＇s in-depth investigation and research, the global Gene Therapy On Cardiovascular Disease market size will reach 599.86 Million USD in 2025 and is projected to reach 25,405.69 Million USD by 2032, with a CAGR of 70.77% (2025-2032). Notably, the China Gene Therapy On Cardiovascular Disease market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Gene therapy for cardiovascular diseases involves the use of genetic interventions to address underlying issues contributing to heart-related disorders. This therapeutic approach aims to modify or introduce specific genes to improve the function of the cardiovascular system. In the context of cardiovascular diseases, gene therapy may target conditions such as ischemic heart disease, heart failure, or genetic disorders affecting cardiac function. Strategies include enhancing blood vessel formation, promoting cell survival, or modulating the expression of genes associated with cardiac health. Researchers are exploring gene therapy approaches to improve angiogenesis, reduce inflammation, and enhance myocardial function. While gene therapy for cardiovascular diseases is still in the experimental stage, early clinical trials and preclinical studies suggest the potential for novel treatment options to address the complex mechanisms involved in these conditions, offering hope for more effective and targeted interventions in the future.
The major global suppliers of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics, bluebird bio, Sunway Biotech, SIBIONO, AnGes, Human Stem Cells Institute, Orchard Therapeutics, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Gene Therapy On Cardiovascular Disease. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Gene Therapy On Cardiovascular Disease market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Gene Therapy On Cardiovascular Disease market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Gene Therapy On Cardiovascular Disease industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Gene Therapy On Cardiovascular Disease Include:
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Human Stem Cells Institute
Orchard Therapeutics
Gene Therapy On Cardiovascular Disease Product Segment Include:
Viral Gene Therapy
Non-Viral Gene Therapy
Gene Therapy On Cardiovascular Disease Product Application Include:
Neurological Diseases
Cancer
Other
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Gene Therapy On Cardiovascular Disease Industry PESTEL Analysis
Chapter 3: Global Gene Therapy On Cardiovascular Disease Industry Porter's Five Forces Analysis
Chapter 4: Global Gene Therapy On Cardiovascular Disease Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Gene Therapy On Cardiovascular Disease Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Gene Therapy On Cardiovascular Disease Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Gene Therapy On Cardiovascular Disease Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Gene Therapy On Cardiovascular Disease Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Gene Therapy On Cardiovascular Disease Product by Type
- 1.2.1 Viral Gene Therapy
- 1.2.2 Non-Viral Gene Therapy
- 1.3 Gene Therapy On Cardiovascular Disease Product by Application
- 1.3.1 Neurological Diseases
- 1.3.2 Cancer
- 1.3.3 Other
- 1.4 Global Gene Therapy On Cardiovascular Disease Market Size Analysis (2020-2032)
- 1.5 Gene Therapy On Cardiovascular Disease Market Development Status and Trends
- 1.5.1 Gene Therapy On Cardiovascular Disease Industry Development Status Analysis
- 1.5.2 Gene Therapy On Cardiovascular Disease Industry Development Trends Analysis
- 2 Gene Therapy On Cardiovascular Disease Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Gene Therapy On Cardiovascular Disease Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Gene Therapy On Cardiovascular Disease Market Analysis by Country
- 4.1 Global Gene Therapy On Cardiovascular Disease Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Gene Therapy On Cardiovascular Disease Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Gene Therapy On Cardiovascular Disease Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.5 China Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.6 France Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.14 India Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Gene Therapy On Cardiovascular Disease Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Gene Therapy On Cardiovascular Disease Market Revenue by Key Suppliers (2021-2025)
- 5.2 Gene Therapy On Cardiovascular Disease Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Gene Therapy On Cardiovascular Disease Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Gene Therapy On Cardiovascular Disease Market Analysis by Type
- 6.1 Global Gene Therapy On Cardiovascular Disease Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Gene Therapy On Cardiovascular Disease Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Biogen
- 7.1.1 Biogen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Biogen Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.1.3 Biogen Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Novartis
- 7.2.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Novartis Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.2.3 Novartis Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Gilead Sciences
- 7.3.1 Gilead Sciences Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Sarepta Therapeutics
- 7.4.1 Sarepta Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Alnylam Pharmaceuticals
- 7.5.1 Alnylam Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 Amgen
- 7.6.1 Amgen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Amgen Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.6.3 Amgen Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 Spark Therapeutics
- 7.7.1 Spark Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Akcea Therapeutics
- 7.8.1 Akcea Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 bluebird bio
- 7.9.1 bluebird bio Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Sunway Biotech
- 7.10.1 Sunway Biotech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.11 SIBIONO
- 7.11.1 SIBIONO Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio
- 7.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Market Data Analysis (Revenue, Gross Margin and
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
